Experts are now urging the FDA to ban the use of phenylpropanolamine (PPA) in OTC products

Experts are now urging the FDA to ban the use of phenylpropanolamine (PPA) in OTC products.

This is due to a possible increased risk of hemorrhagic stroke...especially in young women taking high doses for weight loss.

For now, warn patients not to exceed recommended doses of PPA-containing products...Acutrim, Dexatrim, Contac, Dimetapp, etc.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote